{"entity":{"id":"paper-piha-paul-talazoparib-ddr-npj-2024","kind":"paper","name":"Talazoparib in advanced cancers with BRCA1/2, DNA repair and PTEN alterations","aka":[],"tldr":"Talazoparib helped some people with advanced cancers carrying tumour-only BRCA mutations. The study was small and included several cancer types.","summary":"Phase 2 molecular basket, median four prior lines of therapy. Cohorts included somatic BRCA1/2, other homologous-recombination repair genes, PTEN and germline BRCA1/2 in cancers outside breast/ovarian indications. Clinical benefit included response or stable disease lasting at least 24 weeks.","asOf":"2026-10-10","links":[{"label":"Primary publication","url":"https://doi.org/10.1038/s41698-024-00634-6"},{"label":"PubMed record","url":"https://pubmed.ncbi.nlm.nih.gov/39085400/"}],"tags":[],"related":[],"cancers":["breast-cancer","tnbc"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["talazoparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct02286687"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"npj Precision Oncology","year":2024,"doi":"10.1038/s41698-024-00634-6","pmid":"39085400","authors":"Piha-Paul SA, Tseng C, Leung CH, et al.","paperType":"translational","findings":["Somatic BRCA1/2 cohort: four objective responses among 18 patients, ORR 22.2% (95% CI 6.4 to 47.6); six clinical-benefit events.","Posterior mean clinical-benefit rate 32.5% (90% credible interval 16.7 to 50.3) is a separate endpoint from objective response.","Breast examples included a somatic BRCA1 partial response and prolonged stable disease."],"whatItMeans":"Mixed, heavily pretreated cancers and no control arm; cannot compare its ORR directly with olaparib trials or establish postoperative benefit.","caveats":["Mixed, heavily pretreated cancers and no control arm; cannot compare its ORR directly with olaparib trials or establish postoperative benefit."],"participants":79},"route":"/key-papers/paper-piha-paul-talazoparib-ddr-npj-2024/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/"}],"trial":[{"id":"nct02286687","kind":"trial","name":"Talazoparib molecular basket in advanced cancers","route":"/trials/nct02286687/"}]}}